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ABSTRACT: 4-methylmethcathinone (mephedrone) has emerged in drug seizures as a new psychoactive substance (NPS) causing 
a public health risk of global concern. Currently, there are no commercial microfluidic devices for the selective detection of 
mephedrone and so this study presents a simple, low cost and portable paper-based Lab-on-a-Chip (LOC) device with colorimetric 
detection to fill this gap. Limits of detection for mephedrone in spiked urine and dissolved powder (aqueous) samples are clinically 
relevant at 4.34 ng mL-1 and 2.51 ng mL-1 respectively. No cross-reactivity for commonly encountered cutting agents, interferents 
and adulterants were detected. Mephedrone and its main metabolite were detectable in aqueous samples within 3 minutes. Stability 
and reproducibility measurements showed no significant difference in signal intensity over eight weeks and no significant difference 
within or between devices. The proposed device has the potential to provide cost-effective, rapid, on-site testing within forensic or 
clinical settings and therefore has wide global applicability. 
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1. INTRODUCTION 
Miniaturization of bioanalytical techniques for the creation of 
portable toolkits has been driven by microfluidics: the use of 
small systems containing micron size channels allows the 
integration of multiple processes to produce Lab-on-a-Chip 
(LOC) devices. This offers significant advantages over their 
conventional counterparts including; reduced sample and reagent 
consumption which is ideal for forensic and clinical applications; 
reduced waste; faster reaction times; reduced cost and increased 
portability [1]. In particular, paper-based microfluidic devices are 
very cost-effective due to the nature of the substrate and are easy 
to fabricate. For example, using wax printing to create the 
required design generates hydrophobic barriers surrounding 
hydrophilic channels for movement of solutions. Fluid transport 
is driven by capillary action and therefore no external power 
source is required. In addition, the high surface area to volume 
ratio aids detection limits when colorimetric methods are used 
[2]. A wide variety of fabrication methods and biological 
applications of paper-based microfluidic devices have previously 
been shown and are summarized in a number of recent reviews 
[2-5]. The analysis of drugs of abuse from biological matrices 
using microfluidic devices has mainly focused on extraction and 
separation of samples, as presented in a review by Al-Hetlani [6].
Microfluidic immunoassays have been reported as rapid 
screening tests, and while the focus has mainly been on clinical 
diagnostics, for example the detection of circulating tumour cells 
[7], there has been limited interest in drugs of abuse. This has 
included detection of performance enhancing drugs in sport, such 
as testosterone [8], as well as multiplex detection of recreational 
drugs of abuse using electrochemical [9], optical [10], 
chemiluminescent [11], immunological [12] and colorimetric 
techniques [13]. 
New Psychoactive Substances (NPSs) are substances that are 
new to the recreational drugs market, exhibiting a psychoactive 
effect when taken, thus presenting a serious risk to public health 
[14]. NPSs (formerly known as “legal highs”) exhibit similar 
biological and pharmacological activity to controlled drugs of 
abuse, such as cannabis and amphetamines, but with limited 
knowledge regarding the pharmacology and potential health risks 
[15]. The most recent report from the United Nations Office on 
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Drugs and Crime (UNODC) stated that there were 803 NPSs 
reported globally from 2009-2017, of which 148 were reported as 
synthetic cathinones, including mephedrone [16]. There has been 
an increase in the availability of NPSs in prisons reported across 
Europe. This has resulted in subsequent increases in violence, 
bullying, aggressive behavior and debt as a consequence of high 
mark up prices is also having a detrimental effect, which is still a 
significant issue in United Kingdom (UK) prisons even after the 
introduction of the Psychoactive Substances Act 2016 [17]. The 
most recent reports from the Office for National Statistics 
regarding drug-related deaths in England and Wales states that 
deaths involving NPSs are increasing with 125 NPS related 
deaths registered in 2018 [18]. Deaths directly related to NPS use 
within prisons can be complex and can often be under reported 
[19]. This is due to number of complications including the lack 
of reference standards for NPSs, detecting low concentrations of 
NPSs, and the commonly encountered issue that NPSs are taken 
with other recreational drugs, known as poly-drug use [19,20]. 
For example, 79 NPS-related deaths were reported in prisons in 
England and Wales between June 2013 and September 2016 even 
after the introduction of the NPS Act 2016 in the UK on the 26th 
of May 2016 made it illegal to supply, possess, export or import 
NPSs [19,20].
The synthetic cathinone, mephedrone first appeared on the 
recreational drug market in the 2007, where it has established a 
place for itself on the recreational drugs market globally, but is a 
significant problem in the UK [21]. This is especially true in the 
UK where it has been identified as the most common widely 
abused NPS [21]. Mephedrone is a synthetic derivative of 
cathinone, naturally found in the Catha edulis plant and exhibits 
similar effects to amphetamine [22]. Mephedrone is most 
commonly found in powder or tablet forms [22]. In 2015, at the 
58th Commission on Narcotic Drugs (CND) in Vienna, 
mephedrone was the first NPS to be listed in Schedule II of the 
United Nations 1971 Convention of Psychotropic Substances 
(decision 58/1), placing it under international control [23,24]. In 
relation to other drugs of abuse, such as cocaine and heroin, these 
numbers may be deemed as small in consequence but the use of 
NPSs has increased throughout the UK severely putting strain on 
public services, including Accident and Emergency departments 
and prisons.
Smith et al. [15] reviewed methods for the 
detection/quantification of mephedrone, however many of these 
methods are both non-portable and expensive, and as such are not 
suitable for in-field detection including gas chromatography-
mass spectrometry (GC-MS) [25,26], high performance liquid 
chromatography (HPLC-MS) [27-29] as well as some more 
advanced tandem mass spectrometry (HPLC-HRqTOFMS) [30]. 
However, a recent paper by Elbardisy et al (2019) shows a novel 
electrochemical method using both cyclic voltammetry and 
differential pulse voltammetry for a laboratory-based detection 
method but has the potential for being developed as a portable 
detection method for mephedrone and its metabolites [31]. 
Though supply and production of mephedrone is now controlled 
in the UK, global prevalence is still cause for concern and there 
are no commercial microfluidic devices for the selective 
detection of mephedrone in either pure and/or adulterated 
samples.
Competitive immunoassays are readily utilised for the 
detection of drugs and require only one antibody, along with a 
labelled ‘tracer’ that is a known amount of labelled antigen 
[32,33]. Due to the lack of availability of reference standards for 
the continually increasing number of NPSs available within the 
recreational market, a competitive immunoassay is ideal for 
analysis of NPS. The specific antibody is immobilised to a 
surface, then the tracer and the target antigen within the sample 
compete for the active sites of the antibody [32,33]. An unknown 
amount on unlabelled antigen and a known amount of labelled 
antigen compete for the active sites of the antibody. Therefore, as 
there is a limited number of active sites on the antibody, the 
amount of labelled antigens decreases if there is an increase in the 
concentration of unlabelled antigens, lowering detection 
response. If the sample contains high concentrations of antigen, a 
lower response is produced by 3,3’,5,5’-tetramethylbenzidine 
(TMB), and therefore less color, demonstrating that antigen is 
competing effectively for the active sites of the antibody with the 
HRP-labelled antigen [32,34]. An important and invaluable 
feature of a competitive immunoassay is that structurally similar 
compounds cross-react with one another to varying degrees. For 
example, an antibody specific for 4-MMC with cross-react to 
varying degrees with structurally related compounds, such as its 
metabolites of other synthetic cathinones [32,33]. Due to a 
current lack of reliable low-cost detection methods for NPS, there 
is a timely requirement for a robust portable LOC based solution. 
We address this by presenting a novel paper-microfluidic device 
capable of detecting mephedrone using a competitive 
immunoassay. This device is simple to use, low-cost and 
effective. Its performance was tested by conducting stability 
studies and cross reactivity testing, and its ability to detect the 
presence of mephedrone at clinically relevant levels was proven 
for aqueous and biological (urine) matrices.
2. EXPERIMENTAL SECTION 
The controlled reference standards (cathinone hydrochloride, 
cocaine hydrochloride, amphetamine sulfate and ketamine 
hydrochloride) for this research were obtained from either Sigma-
Aldrich (Gillingham, UK) or Fluorochem Ltd (Hadfield, UK) 
under UK Home Office license, by authorized personnel and in 
compliance with both the UK Misuse of Drugs Act (1971) and 
UK Misuse of Drugs Regulations (2001). All 
controlled/restricted materials were stored, transferred, used and 
destroyed in compliance with the UK Misuse of Drugs Act (1971) 
and UK Misuse of Drugs Regulations (2001).
The synthesis of the racemic target compounds was achieved 
using the previously reported method by Mayer et al [35] in 15% 
(mephedrone and 4-methylephedrine) – 37% (4-
methylcathinone) overall yield. The hydrochloride salts were 
obtained as stable, off-white powders and determined to be 
soluble (10.0 mg mL−1) in deionized water, methanol and 
dimethylsulfoxide (DMSO). To ensure the authenticity of the 
materials utilized in this study the synthesized samples were fully 
structurally characterized by nuclear magnetic resonance (1H and 
13C NMR), GC-MS and Fourier-transform infrared spectroscopy 
with attenuated total reflection (ATR-FTIR) and the purity of all 
samples confirmed by elemental analysis (>99.6% in all cases) 
[35].
2.1. Preparation of Microfluidic Devices 
Paper- based microfluidic devices were designed and printed 
onto Whatman Grade 1 filter paper using a Xerox Phaser 8500 
solid ink printer to produce the design shown in Figure 1. The 
devices were then placed in an oven at 130 ºC for 180 seconds to 
melt the wax and complete the creation of the hydrophobic 
barriers. The reaction wells (black center tab, Figure 1) were then 
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activated by adding 5 µL of 0.250 mg mL-1 chitosan [Sigma-
Aldrich, UK] followed by 5 µL of 2.50 % glutaraldehyde [Sigma-
Aldrich, UK] and then washed twice with 10 µL of analytical 
grade water [33]. The relevant antibody (4 µL) was then added to 
Figure 1 (A). Schematic of the LOC design with central detection zone (black tab); sample tab (green (A)); wash tabs (blue (B) and 
purple (C); and detection reagents tab (yellow (D)). The location of the antibodies is shown using (i) anti-methcathinone; ii) additional 
testing well (for proof of concept anti-amphetamine was added); iii) anti-horseradish peroxidase (HRP) and iv) negative control 
(analytical grade water)) on the central detection zone (black tab). (E)  Thin  blotting  filter  paper  to  be  attached  under  (B),  (F)  Thin  
blotting  filter  paper  to  be  attached  under  (C).   (G)  and  (H)  additional  filter  paper  to  be  attached  under  (E)  and  (F)  for  excess  
water  waste; (B) Image of the printed LOC device with its ‘origami design’. To allow the sequential steps of the immunoassay to take 
place the tabs are folded over the central detection zone (black tab) in order (from A to D). (C) Schematic of the preparation of the LOC 
device; (1) chitosan addition, (2) glutaraldehyde cross-linking. After 2 hours, this was washed twice with analytical grade water. (3) 
antibody addition (i-iv). After 30 minutes, this was then washed twice with analytical grade water. (4) 1% milk powder (blocking buffer) 
was then added. After 15 minutes, this was washed twice with 0.05% PBS-Tween. (5) Labelled and non-labelled antigen addition. This 
was then washed twice with analytical grade water and followed by (6) colorimetric detection using TMB.
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the appropriate well (black center tab, Figure 1): i) anti-methcathinone; ii) additional testing well to enable this device 
to be adapted in the future (for proof of concept anti-amphetamine was added); and iii) anti-horseradish peroxidase 
(HRP). Four microlitres of analytical grade water was added to well iv) as a negative control. The antibodies were 
permanently bound to the microfluidic device through the glutaraldehyde cross-linker. Following a 30-minute 
incubation, the wells were washed twice with 10 µL of analytical grade water in order to remove any unbound 
antibodies. Blocking was then achieved by adding 10 µL of 1 % milk powder (in phosphate buffered saline) solution 
and incubated at room temperature for 15 minutes before washing twice with 10 µL of 0.05% PBS-Tween. The devices 
were either used immediately or stored at 4 °C for a period of up to 4 weeks prior to use in a stability study.
2.2. Conjugation 
The competitive immunoassay required a horseradish peroxidase (HRP) conjugated analyte to compete with the target 
analyte, mephedrone in solution. HRP-conjugation is achieved through interaction of the HRP with a primary amine 
within a target molecule to be conjugated (Figure 2). Mephedrone does not have this functional group, therefore 
cathinone was chosen as the target molecule as it has significant (2200 %) cross-reactivity with the anti-methcathinone 
antibody [36].
Figure 2. Proposed conjugation of cathinone (free base) with horseradish peroxidase (HRP) 
In order to conjugate the HRP to the target molecule, the cathinone firstly needed to be converted into its freebase 
form. In order to expose the amine and inducing a nucleophilic attack in the presence of HRP. A 10.2 mg sample of 
cathinone hydrochloride [Fluorochem Ltd, UK] was dissolved in 500 µL of analytical grade water before being added 
to a 10.0 mg mL-1 solution of sodium hydrogen carbonate (10.0 mg in 1000 µL, Fisher Scientific, UK). Once mixed the 
solution began to effervesce. After the reaction had ceased, the pH of the mixture was taken. A litmus paper test indicated 
a pH of 8 and confirmed that the cathinone was in its freebase form. The aqueous layers of the cathinone were washed 
with diethyl ether (6 x 500 µL, Fisher Scientific) and the organic fractions were combined before the sample was 
evaporated to incipient dryness under nitrogen leaving a pale residue. The residue was reconstituted in 100 µL of 
dimethyl sulphoxide (Sigma-Aldrich, UK) then 10 µL was removed and diluted using 990 µL of PBS (100x dilution, 
Oxoid Ltd. UK) to give a 1 % DMSO/PBS solution. A HRP-conjugation kit [Abcam, UK] was then used as per the 
manufacturer’s standard protocol. 10 µL solution of modifier reagent was added to 100 µL of the cathinone freebase 
solution and mixed. The cathinone freebase-modifier mixture was added to the LYNX lyophilized mix and left to 
incubate overnight at room temperature. After incubation, 10 µL of quencher reagent was added to the mixture and 
incubated at room temperature for 30 minutes prior to use and then stored in aliquots at -20°C until required.
2.3. Immunoassay Protocol 
The LOC device incorporates a competitive immunoassay for the selective detection of mephedrone and 4-
methylcathinone in both urine and aqueous samples. Aqueous samples were prepared by dissolving the target analytes 
of varying concentrations (70.0 ng mL-1 – 0.137 ng mL-1) in molecular grade water. Drug and alcohol-free urine samples 
were donated by healthy volunteers and spiked with target analytes and metabolites at clinically relevant concentrations 
[30]. Ethical approval for this study was obtained through the Research Ethics and Governance Committee at 
Manchester Metropolitan University (Ethics approval number: SE151633A1). Samples were mixed in a 50:50 ratio with 
the HRP-conjugated cathinone and 5 µL was added to each reaction chamber on the microfluidic device (sample tab 
(A), Figure 1). Samples were incubated for 210 seconds before washing twice with molecular grade water (wash waste 
tabs (B) and (C), Figure 1). Finally, 5 µL of 3,3’,5,5’-tetramethylbenzidine (TMB) [Thermo Scientific, UK] was added 
(TMB tab (D), Figure 1) and an image of the color change in the central detection zone (black tab) by taken on an iPhone 
7 and measured using ImageJ analysis (version 1.52a). The color change was proportional to the amount of HRP present. 
Optimisation of the immunoassay was achieved by testing a range of antibody (anti-methcathinone) and labelled antigen 
(cathinone-HRP) concentrations, as well as testing a range of antibody (anti-HRP) and labelled antigen (cathinone-
HRP) concentrations. The inclusion of the anti-HRP antibody provides the microfluidic device a positive control. A 
negative control was also included on the device by replacing the antibody with analytical grade water. The additional 
testing well was included as part of the design to offer future flexibility of the device. As proof of concept, a range of 
concentrations between 0.200 ng mL-1 to 0.050 ng mL-1 of an anti-amphetamine antibody, and labelled-antigen 
concentrations, ranging from 0.200 ng mL-1 to 0.050 ng mL-1 were tested.
2.4. Stability Study 
The signal intensity was recorded over an 8-week period to investigate the stability of the microfluidic device, which 
was subjected to four different storage conditions: fridge (2-8 ºC), freezer (-20 ºC), in the dark at room temperature and 
in the light at room temperature. 
2.5. Cross reactivity using the paper-based LOC device
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The cross-reactivity of the anti-methcathinone antibody with investigated using the immunoassay protocol with 
adulterants (amphetamine, cocaine and ketamine), cutting agents (benzocaine, caffeine, lidocaine, paracetamol, 
procaine and taurine), and interferents (cornflour and flour). A blank sample (no adulterant, cutting agent, or interferent 
present) and a concentration range (7 samples from concentrations 0.156 to 10.0 mg mL-1) of commonly encountered 
adulterants, cutting agents, and interferents was spiked to an aqueous sample and the signal intensity was recorded.
2.6. Data Analysis 
Photographic images were taken of the microfluidic devices using an iPhone 7 once the immunoassay had been 
carried out. Image J software version 1.52a (http://imagej.nih.gov/ij/) was then used to analyze the average intensity of 
each of the wells. The RGB values (blue component) were then transferred into Origin (version 2019) for the graphical 
representations, and SPSS (version 22) and R Studio (version 3.6.1) to allow statistical analysis to be performed. Limits 
of detection (LOD) were determined for the aqueous and biological samples. ANOVA was used to determine if there 
was any difference in signal intensity over an eight-week period. The variation between devices was determined using 
Levene’s test. Linear regression was used to determine if there was any cross-reactivity with the anti-methcathinone 
antibody and any of the adulterants, cutting agents and interferents investigated.
3. RESULTS AND DISCUSSION 
3.1. Method development of Immunoassay Parameters 
Anti-methcathinone antibody concentrations, ranging from 0.020 µg mL-1 to 2.04 mg mL-1, and labelled-antigen 
concentrations, ranging from 0.200 ng mL-1 to 0.025 ng mL-1, were evaluated. It was found that from these parameters 
an antibody concentration of 0.511 mg mL-1 and a labelled-antigen concentration of 0.2 ng mL-1 obtained the best results. 
Anti-HRP antibody concentrations, ranging from 0.200 ng mL-1 to 0.050 ng mL-1, and labelled-antigen concentrations, 
ranging from 0.200 ng mL-1 to 0.025 ng mL-1, were also evaluated in order to determine the most effective concentration 
for this positive control The most effective concentrations were 0.050 ng mL-1  for the anti-HRP antibody and 0.200 ng 
mL-1 for the labelled-antigen concentration.
Therefore, for all future experiments these conditions were used. The additional testing well demonstrates the flexibility 
of this microfluidic device, offering an additional antibody to be included for the detection of an NPS or drugs of abuse. 
.
When mephedrone is present, the TMB will subsequently produce a lower response as the unlabeled target antigen 
(mephedrone) outcompetes the labelled cathinone-HRP for the active sites of the anti-methcathinone antibody. 
Therefore, the higher the average light intensity values, the lower the response of the labelled antigen and the whiter the 
color. If no mephedrone is present, the TMB will subsequently produce a higher response as the unlabeled target antigen 
(mephedrone) is outcompeted the labelled cathinone-HRP for the active sites of the anti-methcathinone antibody. 
Therefore, the lower the average light intensity values, the more intense the reaction color indicating a greater presence 
of HRP (labelled antigen) and therefore less of the unlabeled antigen. The positive control (anti-HRP) and the negative 
control (analytical grade water) were both included in order to increase the reliability of each result when testing using 
this microfluidic device. A positive control was indicated by a blue color change as the HRP (labelled antigen) is 
successfully competing for the active sites on the anti-HRP antibody. Whereas, the negative control was indicated by a 
white color as there is no antibody present in the immunoassay.  The positive (anti-HRP antibody) and negative 
(analytical grade water) controls were effective within the LOC device with signal intensity ranges between 122-139 
and 178-198, respectively.
3.2. Aqueous and Biological Matrices 
Mephedrone containing samples were prepared from both dissolved powder (aqueous) and spiked urine to represent 
the drug in both its pure form and as a clinical specimen. Analysis of the data sets showed a linear range of 0.078 to 
10.0 mg mL-1 for the aqueous and urine samples (Figure 3). The LOD were calculated using regression analysis of the 
aqueous mephedrone and urine sample. The LOD was reported at 3 times the standard deviation (SD) of the intercept 
(3x SD). A LOD of 2.51 ng mL-1 and 4.34 ng mL-1 was calculated for the aqueous mephedrone and urine sample, 
respectively. This is comparable to clinically relevant levels with traditional laboratory methods for mephedrone in 
urine (LOD = 2.00 ng mL-1) achieved by analysis with HPLC-HRqToFMS [30] It is worth noting that the standard 
deviation between replicates of the same mephedrone concentration for both the urine and aqueous samples did show 
some variation within the data. 
Whilst the linear response indicates the potential for the device to be used for full quantitative analysis, there is an 
appreciable degree of variation in measurements, which would hamper the accurate quantitative determination of 
cathinones. It is therefore recommended that this device is used only to confirm the presence of a cathinones in 
concentrations greater than 2.51 ng mL-1 in aqueous samples and 4.34 ng mL-1 in urine.
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Figure 3. Detection of mephedrone in both aqueous media and spiked urine samples (n = 6)
Mephedrone is metabolised in the body via two different Phase 1 processes (Figure 4), the main route of metabolism 
is via a primary route of demethylation in order to form a cathinone product. Due to the high degree of cross-reactivity 
associated with the anti-methcathinone antibody and the positive results obtained with both mephedrone and cathinone-
HRP conjugate, the same concentration range was applied to samples of methcathinone, cathinone, 4-methylcathinone 
and 4-methylephedrine. Analysis of the data collected confirmed that the anti-methcathinone antibody did in fact cross-
react with all members of the cathinone family tested at clinically relevant levels (0.137 to 70 ng mL-1). With the 
metabolite and parent compound cathinone demonstrating the greatest affinity with the greatest response, followed by 





















Figure 4. Structures of cathinone, methcathinone and the proposed route for the Phase I metabolism of mephedrone 
(Adapted from Khreit et al. [37]).
Both cathinone and 4-methylcathinone had linear ranges between 0.20-5.00 ng mL-1. Thus, demonstrating that both the 
4-methylcathinone and the cathinone are successfully competing with the cathinone-HRP for the active sites on the 
antibodies and that even small changes in the drug concentration affect the amount of cathinone-HRP present. Positive 
results were also observed for another common cathinone derivative, methcathinone and its primary metabolite, 4-
methylephedrine. However, both the light intensity values and the calibration curves were weaker than those previously 
seen indicating that even though they both successfully compete for the active sites on the antibodies their binding 
affinity is not as strong as the mephedrone metabolites, making them harder to detect.Therefore, this LOC device can 
identify the presence, but it is for non-quantitative analysis and cannot distinguish between structurally similar synthetic 
cathinones at varying concentrations.
3.3. Stability Study 
A control immunoassay experiment to investigate the stability of the microfluidic device was performed by subjecting 
the device to four different storage conditions; fridge (2-8 ºC), freezer (-20 ºC), in the dark at room temperature and in 
the light at room temperature. The signal intensity was recorded over the 8 weeks and showed that there was no 
significant difference between the values recorded over the time period (ANOVA: F = 2.134, df = 1, p = 0.146) (Figure 
5). However, there was a significant difference between the four conditions (ANOVA: F = 12.741, df = 3, p < 0.001). 
Three of the four conditions (fridge, freezer, and light at room temperature) were not significant indicating that these 
three conditions were stable for the eight week period and could all therefore effectively used as suitable storage 
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conditions. The significant difference in the LOC devices stored in the dark at room temperature (p < 0.001) indicates 
that the LOC devices were not stable in this condition, and therefore storage in this was is not recommended.
Figure 5. Signal intensity recorded over a 8 week period to investigate the stability of the microfluidic devices (n = 
18).
Variation within four individual microfluidic devices was assessed using Levene’s test, which indicated equal 
variances (p = 0.638) indicating that intra-device variability was observed. Inter-device variation was then examined to 
examine the reliability of the manufacturing (Figure 5). This showed that there was no significant difference between 
devices (ANOVA: F (3, 47) = 2.10, p = 0.114).
Figure 5. Signal intensity recorded across four different microfluidic devices (n = 12).
3.4. Cross-reactivity using the paper-based LOC device 
The cross-reactivity of the anti-methcathinone antibody with the adulterants, cutting agents and interferents at varying 
concentrations was investigated. Linear regression analysis (Table 1) showed that there was no detrimental cross-
reactivity for any adulterants, cutting agents, or interferents investigated. There was no statistically significant increase 
between the response, and the concentration of the adulterants, cutting agents, or interferents in the spiked samples. This 
indicates that the level of cathinone-HRP binding to the antibody is consistent across the dilution ranges of the 
adulterants, as well as the cutting agents and interferents.
Table 1: Summary table for linear regression analysis cross-reactivity of cutting agents, adulterants and interferents
Adulterants/
cutting agent
Compound P-Value Adjusted R-
squared











corn flour 0.0789 0.00321Interferents
flour 0.0983 0.00289
3.5. Additional adaptable functionality using the paper-based LOC device 
This microfluidic device offers future flexibility for additional testing of other NPS or drugs of abuse. This was 
demonstrated by using well ii (Figure 1) for the simultaneous determination of amphetamine. For this proof of concept, 
a range of anti-amphetamine antibody concentrations (0.200 ng mL-1 to 0.050 ng mL-1), and labelled-antigen 
concentrations, (0.200 ng mL-1 to 0.050 ng mL-1) were trialed. By using an optimum concentration of anti-amphetamine 
antibody at 1.75 ng mL-1 and a labelled-antigen concentration of 0.200 ng mL-1, this enabled the microfluidic device to 
detect amphetamine in at a level of 10 mg mL-1 in dissolved powder (aqueous). These results demonstrate how this 
microfluidic device can be easily adapted to suit future and specific research trends in different geographical locations 
around the globe. 
4. Conclusions 
This study has successfully demonstrated that this paper-based LOC device can detect clinically significant levels of 
mephedrone and its metabolites in dissolved powder (aqueous) and spiked urine samples. The limits of detection of the 
device are 2.51 ng mL-1 (aqueous) and 4.34 ng mL-1 (urine), which is comparable with traditional laboratory methods of 
2 ng mL-1 achieved by HPLC-HRqToFMS [30]. The devised method has successfully encompassed many of the 
advantages associated with microfluidic devices; it is both low cost and easy to produce, the incubation and overall 
reaction time has been reduced from days on a standard 96 well plate to minutes on the paper-based device and both the 
reagent and sample volumes required have been reduced to microlitre quantities.
Thus, supporting the reliability of this microfluidic device for future testing of mephedrone and its metabolites. This 
microfluidic device also has the advantage for future flexibility as the additional testing well was easily adaptable by 
effectively optimizing a range of anti-amphetamine antibody concentrations and labelled-antigen concentrations for the 
specific detection of amphetamine. Therefore, providing proof of concept that this microfluidic device has multiplex 
potential, showing flexibility to suit future research projects for the detection of other NPSs or drugs of abuse. 
The application of an intra-inter stability study showed that there was no significant difference between 
different LOC devices, successfully signifying that tests carried out across a range of different plates were 
reproducible. Stability studies indicated that the LOC devices stored in the four different conditions were stable for up 
to eight weeks. The stability demonstrated by this LOC device would allow for more widespread use of the point-of-
care (POC) test and enable optimisation and pre-coating with the primary antibody to occur prior to distribution. 
This method has proved successful at differentiating cathinones from other adulterants, cutting agents, and 
interferents. Spiking studies identified no cross-reactivity in the presence of cocaine, ketamine, paracetamol, 
benzocaine, caffeine, lidocaine, procaine, taurine, sucrose, cornflour and flour. The results show that this proposed 
device has the potential to provide rapid, on-site testing within either a forensic or clinical setting in biological samples 
(urine), but also in aqueous samples that may have been ‘cut’ with diluents or administered with other drugs of abuse. 
The low-cost of the device is highly beneficial as it can be used in low income countries, giving it a wide global 
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Highlights
 Mephedrone, a synthetic cathinone, is a widely used new psychoactive substance 
 We present a Lab-on-a-Chip to detect mephedrone at clinically relevant levels 
 Cross-reactivity with common adulterants, stability and reproducibility were 
examined 
 Using a Lab-on-a-Chip enables rapid (< 3 minutes), low-cost, on-site detection
